High-bleeding-risk patients who underwent implantation with the sirolimus-eluting, biodegradable polymer Ultimaster stent had similar adverse cardiac and cerebral events – but lower bleeding events – when given shorter courses of dual antiplatelet therapy (DAPT), “regardless of PCI complexity, according to a new analysis of the MASTER DAPT trial presented Tuesday at EuroPCR 2022 in Paris.